Loading clinical trials...
Loading clinical trials...
A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients With Type 2 Diabetes Mellitus
Conditions
Interventions
LY3209590
Insulin Degludec
Locations
64
United States
Syed Research Consultants Llc
Sheffield, Alabama, United States
National Research Institute - Huntington Park
Huntington Park, California, United States
National Research Institute - Wilshire
Los Angeles, California, United States
Catalina Research Institute, LLC
Montclair, California, United States
Encompass Clinical Research
Spring Valley, California, United States
CMR of Greater New Haven
Waterbury, Connecticut, United States
Start Date
July 1, 2020
Primary Completion Date
October 8, 2021
Completion Date
October 8, 2021
Last Updated
November 2, 2022
NCT07232537
NCT06278207
NCT07051005
NCT06887049
NCT04943861
NCT07433062
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions